1. Report Introduction

2. Mucopolysaccharidosis I Market Overview at a Glance
2.1. Market Share Distribution of Mucopolysaccharidosis I in 2018
2.2. Market Share Distribution of Mucopolysaccharidosis I in 2028

3. Disease Background and Overview: Mucopolysaccharidosis I
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Mucopolysaccharidosis I in 7MM
4.3. Total Prevalent Patient Population of Mucopolysaccharidosis I in 7MM – By Countries

5. Epidemiology of Mucopolysaccharidosis I by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.1.3. Sub-Type Specific cases of the Mucopolysaccharidosis I *Indication Specific
5.1.4. Sex- Specific Cases of the Mucopolysaccharidosis I*Indication Specific
5.1.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.1.6. Treatable Cases of the Mucopolysaccharidosis I
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.4.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.4.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.4.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.4.6. Treatable Cases of the Mucopolysaccharidosis I
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.5.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.5.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.5.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.5.6. Treatable Cases of the Mucopolysaccharidosis I
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.6.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.6.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.6.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.6.6. Treatable Cases of the Mucopolysaccharidosis I
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.7.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.7.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.7.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.7.6. Treatable Cases of the Mucopolysaccharidosis I
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.8.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.8.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.8.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.8.6. Treatable Cases of the Mucopolysaccharidosis I
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.9.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.9.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.9.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.9.6. Treatable Cases of the Mucopolysaccharidosis I

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Mucopolysaccharidosis I

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Mucopolysaccharidosis I
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Mucopolysaccharidosis I: 7MM Market Analysis
12.1. 7MM Market Size of Mucopolysaccharidosis I
12.2. 7MM Percentage Share of drugs marketed for Mucopolysaccharidosis I
12.3. 7MM Market Sales of Mucopolysaccharidosis I by Products

13. Mucopolysaccharidosis I: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Mucopolysaccharidosis I in United States
13.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in United States
13.1.3. Market Sales of Mucopolysaccharidosis I by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Mucopolysaccharidosis I in Germany
13.2.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Germany
13.2.1.3. Market Sales of Mucopolysaccharidosis I by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Mucopolysaccharidosis I in France
13.2.2.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in France
13.2.2.3. Market Sales of Mucopolysaccharidosis I by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Mucopolysaccharidosis I in Italy
13.2.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Italy
13.2.3.3. Market Sales of Mucopolysaccharidosis I by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Mucopolysaccharidosis I in Spain
13.2.4.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Spain
13.2.4.3. Market Sales of Mucopolysaccharidosis I by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Mucopolysaccharidosis I in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in United Kingdom
13.2.5.3. Market Sales of Mucopolysaccharidosis I by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Mucopolysaccharidosis I in Japan
13.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Japan
13.3.3. Market Sales of Mucopolysaccharidosis I by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight